1
|
Mester-Tonczar J, Einzinger P, Hasimbegovic E, Kastner N, Schweiger V, Spannbauer A, Han E, Müller-Zlabinger K, Traxler-Weidenauer D, Bergler-Klein J, Gyöngyösi M, Lukovic D. A CircRNA-miRNA-mRNA Network for Exploring Doxorubicin- and Myocet-Induced Cardiotoxicity in a Translational Porcine Model. Biomolecules 2023; 13:1711. [PMID: 38136582 PMCID: PMC10741657 DOI: 10.3390/biom13121711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 11/14/2023] [Accepted: 11/23/2023] [Indexed: 12/24/2023] Open
Abstract
Despite the widespread use of doxorubicin (DOX) as a chemotherapeutic agent, its severe cumulative cardiotoxicity represents a significant limitation. While the liposomal encapsulation of doxorubicin (Myocet, MYO) reduces cardiotoxicity, it is crucial to understand the molecular background of doxorubicin-induced cardiotoxicity. Here, we examined circular RNA expression in a translational model of pigs treated with either DOX or MYO and its potential impact on the global gene expression pattern in the myocardium. This study furthers our knowledge about the regulatory network of circRNA/miRNA/mRNA and its interaction with chemotherapeutics. Domestic pigs were treated with three cycles of anthracycline drugs (DOX, n = 5; MYO, n = 5) to induce cardiotoxicity. Untreated animals served as controls (control, n = 3). We applied a bulk mRNA-seq approach and the CIRIquant algorithm to identify circRNAs. The most differentially regulated circRNAs were validated under cell culture conditions, following forecasting of the circRNA-miRNA-mRNA network. We identified eight novel significantly regulated circRNAs from exonic and mitochondrial regions in the porcine myocardium. The forecasted circRNA-miRNA-mRNA network suggested candidate circRNAs that sponge miR-17, miR-15b, miR-130b, the let-7 family, and miR125, together with their mRNA targets. The identified circRNA-miRNA-mRNA network provides an updated, coherent view of the mechanisms involved in anthracycline-induced cardiotoxicity.
Collapse
Affiliation(s)
- Julia Mester-Tonczar
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Patrick Einzinger
- Research Unit of Information and Software, Institute of Information Systems Engineering, 1040 Vienna, Austria;
| | - Ena Hasimbegovic
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Nina Kastner
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Victor Schweiger
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Andreas Spannbauer
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Emilie Han
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Katrin Müller-Zlabinger
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Denise Traxler-Weidenauer
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Jutta Bergler-Klein
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Mariann Gyöngyösi
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| | - Dominika Lukovic
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria; (J.M.-T.); (E.H.); (N.K.); (V.S.); (A.S.); (K.M.-Z.); (D.T.-W.); (J.B.-K.); (M.G.)
| |
Collapse
|
2
|
Viale M, Bertone V, Maric I, Cilli M, Emionite L, Bocchini V, Ponzoni M, Fontana V, De Luca F, Rocco M. Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma. Pharmacol Res 2021; 163:105294. [PMID: 33217536 DOI: 10.1016/j.phrs.2020.105294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 09/30/2020] [Accepted: 11/02/2020] [Indexed: 12/12/2022]
Abstract
Caelyx and Myocet are clinically used liposomal forms of doxorubicin (Dox). To explore ways to improve their therapeutic index, we have studied their activity in vitro and in vivo when locally delivered by fibrin gels (FBGs). In vivo local toxic and anti-tumour activities of loaded FBGs were assessed in two immunodeficient mouse orthotopic human neuroblastoma (NB) models after application in the visceral space above the adrenal gland, either still tumour-bearing or after tumour removal. In parallel, in vitro assays were used to mimic the in vivo overlaying of FBGs on the tumour surface. FBGs were prepared with different concentrations of fibrinogen (FG) and clotted in the presence of Ca2+ and thrombin. The in vitro assays showed that FBGs loaded with Myocet possess a cytotoxic activity against NB cell lines generally greater than those loaded with free Dox or Caelyx. In vivo FBGs loaded with Myocet showed lower general and local toxicities as compared to gels loaded with Caelyx or free Dox, and also to free Dox administered i.v. (all treatments with Dox at 2.5 mg/Kg). The anti-tumour activity, evaluated in the two mouse orthotopic NB models of adjuvant and neo-adjuvant therapy, resulted in a better performance of FBGs loaded with Myocet compared to the other local (FBGs loaded with Caelyx or free Dox) or systemic (free Dox) treatments (administered at 2.5 and 5 mg/Kg Dox). Specifically, the application of FBGs at 40 mg/mL in the adjuvant model caused 92 % tumour volume reduction, while by the neo-adjuvant application of FBGs at 22 mg/mL a re-growing tumour volume reduction of 89 % was obtained. Taken together, our in vitro and in vivo results indicate a significantly higher activity for the FBGs loaded with Myocet. In particular, the lower toicity coupled with the higher anti-tumour activity on both the local treatment modalities strongly suggest a better therapeutic index when Myocet is administered through FBGs. Therefore, FBGs loaded with Myocet may be considered as a possible new tool for the loco-regional treatment of NB or even other tumour histotypes treatable by loco-regional chemotherapy.
Collapse
Affiliation(s)
- Maurizio Viale
- UOC Bioterapie, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genova, Italy.
| | - Vittorio Bertone
- Università di Pavia "L. Spallanzani", Dipartimento Biologia e Biotecnologie, Lab. Anatomia Comparata e Citologia, Via Ferrata 9, 27100, Pavia, Italy.
| | - Irena Maric
- UOC Bioterapie, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genova, Italy
| | - Michele Cilli
- UOS Animal Facility, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genova, Italy.
| | - Laura Emionite
- UOS Animal Facility, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genova, Italy.
| | - Vittorio Bocchini
- Segreteria Comitato Etico Regione Liguria, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genova, Italy.
| | - Mirco Ponzoni
- Laboratorio Terapie Sperimentali in Oncologia, Istituto G. Gaslini, Via G. Gaslini 5, 16147, Genova, Italy.
| | - Vincenzo Fontana
- UOC Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genova, Italy.
| | - Fabrizio De Luca
- Università di Pavia "L. Spallanzani", Dipartimento Biologia e Biotecnologie, Lab. Biologia Cellulare e Neurobiologia, Via Ferrata 9, 27100, Pavia, Italy.
| | - Mattia Rocco
- UOS Biopolimeri e Proteomica, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genova, Italy.
| |
Collapse
|
3
|
Jung S, Nagy Z, Fassnacht M, Zambetti G, Weiss M, Reincke M, Igaz P, Beuschlein F, Hantel C. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Endocr Relat Cancer 2016; 23:825-37. [PMID: 27550961 DOI: 10.1530/erc-16-0249] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 08/22/2016] [Indexed: 02/02/2023]
Abstract
Systemic therapy of adrenocortical carcinoma (ACC) is limited by heterogeneous tumor response and adverse effects. Recently, we demonstrated anti-tumor activity of LEDP-M (etoposide, liposomal doxorubicin, liposomal cisplatin, mitotane), a liposomal variant of EDP-M (etoposide, doxorubicin, cisplatin, mitotane). To improve the therapeutic efficacy and off-target profiles of the clinical gold standard EDP-M, we investigated liposomal EDP-M regimens in different preclinical settings and in a small number of ACC patients with very advanced disease. Short- and long-term experiments were performed on two ACC models (SW-13 and SJ-ACC3) in vivo We evaluated the anti-tumoral effects and off-target profiles of EDP-M, LEDP-M and a novel regimen L(l)EDP-M including liposomal etoposide. Furthermore, the role of plasma microRNA-210 as a therapeutic biomarker and first clinical data were assessed. Classical and liposomal protocols revealed anti-proliferative efficacy against SW-13 (EDP-M P < 0.01; LEDP-M: P < 0.001; L(l)EDP-M: P < 0.001 vs controls), whereas in SJ-ACC3, only EDP-M (P < 0.05 vs controls) was slightly effective. Long-term experiments in SW-13 demonstrated anti-tumor efficacy for all treatment schemes (EDP-M: P < 0.01, LEDP-M: P < 0.05, L(l)EDP-M P < 0.001 vs controls). The analysis of pre-defined criteria leading to study termination revealed significant differences for control (P < 0.0001) and EDP-M (P = 0.003) compared to L(l)EDP-M treatment. Raising its potential for therapy monitoring, we detected elevated levels of circulating microRNA-210 in SW-13 after LEDP-M treatment (P < 0.05). In contrast, no comparable effects were detectable for SJ-ACC3. However, overall histological evaluation demonstrated improved off-target profiles following liposomal regimens. The first clinical data indicate improved tolerability of liposomal EDP-M, thus confirming our results. In summary, liposomal EDP-M regimens represent promising treatment options to improve clinical treatment of ACC.
Collapse
Affiliation(s)
- Sara Jung
- Endocrine Research UnitMedizinische Klinik und Poliklinik IV, Ludwig-Maximilians-University, Munich, Germany
| | - Zoltan Nagy
- 2nd Department of MedicineSemmelweis University, Faculty of Medicine, Budapest, Hungary
| | - Martin Fassnacht
- Department of Internal Medicine IDivision of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany Comprehensive Cancer Center MainfrankenUniversity of Würzburg, Würzburg, Germany
| | - Gerard Zambetti
- Department of PathologySt Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Max Weiss
- Institute of PathologyLudwig-Maximilians-University, Munich, Germany
| | - Martin Reincke
- Endocrine Research UnitMedizinische Klinik und Poliklinik IV, Ludwig-Maximilians-University, Munich, Germany
| | - Peter Igaz
- 2nd Department of MedicineSemmelweis University, Faculty of Medicine, Budapest, Hungary
| | - Felix Beuschlein
- Endocrine Research UnitMedizinische Klinik und Poliklinik IV, Ludwig-Maximilians-University, Munich, Germany
| | - Constanze Hantel
- Endocrine Research UnitMedizinische Klinik und Poliklinik IV, Ludwig-Maximilians-University, Munich, Germany
| |
Collapse
|